We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy. Hide

25th Process Development Symposium - conference papers

Process development

This item first appeared in 2007

Churchill College, Cambridge, 5-7 December 2007

The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry as well as enabling technologies.

The symposium aimed to bring together a wide range of speakers from across the pharmaceutical, agrochemical and fine chemical industries as well as from an academic background.

Wednesday 5 December
Chairman - Dr David Lathbury, AstraZeneca, UK
13:40   Diastereoselective Reductive Amination of 2,2,2- Trifl uoroacetophenones and a-Aminoesters (pdf 280Kb)
Dr Greg Hughes, Merck-Frosst, Canada
14:20   Process Aspects of Asymmetric Hydrogenation (pdf 680Kb)
Dr Ian Lennon, DowPharma, UK
15:00   Lab Automation within Roche Synthesis & Process Research and Kilolaboratory
Dr Jean-Michel Adam, F. Hoffman-La Roche Ltd., Switzerland
15:40   Tea
Process Chemistry Retrospectives
16:10   SK&F92334 - Chemical Development of the Original Blockbuster
Dr Mike Forth, GlaxoSmithKline, UK
16:40   Atenolol - 30 years of Life Cycle Management (pdf 2.2Mb)
Dr Stewart Jolly, AstraZeneca, UK
17:10   'A Blast from the Past' - Removal of Azide Protection in the Identification and Development of a Manufacturing Process to Amlodipine (pdf 80Kb)
Mr Alan Pettman, Pfizer Global Research & Development, UK
Thursday 6 December
Chairman- Dr Martin Jones, AstraZeneca, UK
09:00   MK-524 - A Study in Modern Chemical Development (pdf 1.3Mb)
Dr Edward Grabowski, Merck Research Laboratories (retired), USA
10:00   The Chemical Development of Tofi milast a PDE4 Inhibitor for Asthma and COPD (pdf 350 Kb)
Dr Lorraine Murtagh, Pfizer Global Research & Development, UK
10:40   Coffee
11:10   ZK-EPO, Chemical Development of a Totally Synthetic Epothilone Anti Cancer Drug
Dr Harribert Neh, Bayer Schering Pharma AG, Germany
11:50   Green Manufacture of Chiral Alcohols using Custom Evolved Biocatalysts - Replacing Boron Based Reducing Agents
Dr Jim Lalonde, Codexis Inc, USA
12:30   The Optimization and Scale-up Synthesis of BCL-2 Inhibitors
Dr David Hill, Abbott Laboratories, USA
Chairman - Dr John Carey, GlaxoSmithKline, UK

Large-Scale Application of Microreaction Technology within Commercial Chemical Production of DSM 
Dr Peter Poechlauer, DSM Pharmaceutical Products, Austria

14:50   The Synthesis of 9-Oxa-3,7-diazabicyclo[3.3.1]nonanes (Oxabispidines) and their use as Pharmaceutical Intermediates
Dr David Cladingboel, AstraZeneca, UK
16:00   Increasing Process Understanding through Data Analysis (pdf 500Kb)
Dr Alan Brown, Syngenta, UK
16:40   Process Research over 25 Years: A Personal Perspective (pdf 4.5Mb)
Professor Steven Ley, University of Cambridge, UK
Friday 7 December
Chairman - Dr Graham McDougald, Syngenta, UK
09:00   Process Development of Brivanib Alaninate, a VEGRF/FGFR Inhibitor
Dr Paul Lobben, Bristol-Myers Squibb, USA
09:40   Directed Evolution of Enzymes: New Biocatalysts for Organic Synthesis
Professor Nick Turner, University of Manchester Winner of GlaxoSmithKline, AstraZeneca and Pfizer Prize for Process Chemistry Research 2007
11:10   Redesigning and Developing the Synthetic Route to 435466
Dr David Catterick, GlaxoSmithKline, UK
11:50   Green Chemistry in the Pharmaceutical Industry
Dr Andy Wells, AstraZeneca, UK


Related Links

Share this article